The table below shows Viking Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$113.98M
-$52.33M
-$6.13M
-$24.64M
-$10.53M
-$10.88M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
$54.19M
$63.24M
-$459.79M
$2.20M
$1.62M
-$6.63M
Dividends paid
-
-
-
-
-
VKTX operating cash flow (10-K history)
Viking Therapeutics, Inc. reported operating cash flow of -$278.69M for fiscal year 2025. That is down 217.4% from -$87.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$14.76M (FY 2017) to -$278.69M. Figures come from the company's audited annual reports as filed with the SEC.
